-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Upgrades Teva Pharmaceutical Indus to Overweight, Raises Price Target to $23

Benzinga·05/12/2025 12:20:49
Listen to the news
JP Morgan analyst Chris Schott upgrades Teva Pharmaceutical Indus (NYSE:TEVA) from Neutral to Overweight and raises the price target from $21 to $23.